Evidence map›Paper›PMID 39835077›Full record

ReviewCureus2024

Comparison of Efficacy and Safety of Device-Based Interventions Versus Pharmacological Therapy in the Management of Patients With Advanced Parkinson's Disease: A Literature Review.

Waqar Farooqi, Futon A Alabdullkarim, Talal M Abukaram, Lamis Gubran, Deema S Alsulami, Sahar A Albehairi, Fay A Alabdulkarim, Arwa M Wadaan

Abstract readReview
In one paragraph

Review in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Waqar FarooqiInternal Medicine, Almaarefa University, Riyadh, SAU.
Futon A AlabdullkarimPharmacology, Riyadh Elm University, Riyadh, SAU.
Talal M AbukaramCollege of Medicine, Almaarefa University, Riyadh, SAU.
Lamis GubranCollege of Medicine, Almaarefa University, Riyadh, SAU.
Deema S AlsulamiCollege of Medicine, Almaarefa University, Riyadh, SAU.
Sahar A AlbehairiCollege of Medicine, Almaarefa University, Riyadh, SAU.
Fay A AlabdulkarimRespiratory Therapy, Inaya Medical Colleges, Riyadh, SAU.
Arwa M WadaanCollege of Medicine, Almaarefa University, Riyadh, SAU.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Parkinson's disease (PD) is a progressive neurodegenerative disorder characterized by motor and non-motor symptoms that profoundly impact patients' quality of life. While pharmacological therapies such as levodopa remain the mainstay of treatment, their long-term use is often limited by motor complications. Device-based interventions, including deep brain stimulation (DBS) and continuous dopaminergic infusions, have emerged as alternatives, promising sustained symptomatic control and reduced medication-related side effects. This systematic review and meta-analysis evaluate the comparative efficacy, safety, and cost-effectiveness of device-based interventions versus pharmacological therapies in the management of advanced PD. A comprehensive search was conducted across multiple databases to identify randomized controlled trials, observational studies, and systematic reviews. Primary outcomes included motor function improvement, quality of life, and adverse events. Meta-analyses were performed, and subgroup analyses explored the effectiveness of specific interventions. Device-based interventions demonstrated superior efficacy over pharmacological therapies, with a pooled effect size (Cohen's d) of 1.12 (95% confidence interval (CI): 0.94-1.29) for motor symptom control and quality of life improvements. Subgroup analyses showed DBS and levodopa-carbidopa intestinal gel to be particularly effective, with levodopa-carbidopa intestinal gel showing a Cohen's d of 1.25 (95% CI: 0.91-1.58). Device-based therapies also reduced medication dosages and associated motor complications. Sensitivity analyses confirmed the robustness of these findings, and no significant publication bias was detected. However, gaps remain in understanding the long-term outcomes and cost-effectiveness of these interventions. Device-based interventions, especially DBS and levodopa-carbidopa intestinal gel, offer superior symptom control and quality of life improvements compared to traditional pharmacological therapies in advanced PD. These findings support the integration of device-based therapies into personalized treatment strategies. Further research is needed to explore long-term outcomes and establish standardized guidelines for their implementation in clinical practice.

Indexed as

deep brain stimulation (dbs)device-based interventionsmotor symptom managementparkinson’s diseasepharmacological therapies

Identifiers

PMID39835077
PMCPMC11743740

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.